This review discusses the drugs and other substances used to treat abnormal blood lipid levels (dyslipidemia) in order to retard arteriosclerosis. The relationship between dyslipidemia and morbidity and/or mortality from arteriosclerotic cardiovascular disease (ASCVD) has long been established.
|Original language||English (US)|
|Number of pages||24|
|Journal||Annual Review of Pharmacology and Toxicology|
|State||Published - Jan 1 1989|
ASJC Scopus subject areas